• This research compound is the methanesulfonate salt form of dabrafenib; please see the other form of dabrafenib, Cat. No. [D-5678], Dabrafenib, Free Base, for further technical information about both of these research compounds.
• Dabrafenib is the active ingredient in the drug formulation designated by the trade name Tafinlar®. This drug has been used in human clinical trials for patients with BRAF(V600)-mutated metastatic melanoma. NOTE: THE DABRAFENIB, METHANESULFONATE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT TAFINLAR®, AND IS NOT FOR HUMAN USE.
• This dabrafenib product is the methanesulfonate salt, whose CAS number is given above. The CAS number of the free base form is 1195765-45-7.
• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
• Not available in some countries; not available to some institutions; not available for some uses.

Related Terms: